Amgen ($AMGN) announced receiving the FDA acceptance of its Biologics License Application (BLA) seeking approval of Aimovig (erenumab) for the prevention of migraine in patients experiencing at least four migraine days per month. The company will collaborate with Novartis for commercializing the drug in the US.
Insulet ($PODD) announced that it will take control of sales and marketing activities for its Omnipod System in Europe. The company will also manage the distribution and other support activities. Insulet reported that the change will be effective from June 30, 2018 when its current contract with Ypsomed AG expires.